
The all-cash deal is expected to close in December, pending a successful tender offer and other closing conditions.
Merck KGaA has agreed to acquire Rapid Micro Biosystems for $0.75 per share in cash, according to a definitive agreement announced Monday. The deal covers all outstanding shares of Rapid Micro Biosystems.
The transaction is expected to close in December 2026, subject to the successful completion of a tender offer, including a minimum tender condition, and other customary closing conditions. The tender offer has not yet commenced.
Rapid Micro Biosystems shares traded at $0.733, up 12.6% from the previous close, as of 14:50 UTC on Nov. 16. Once the transaction is completed, Rapid will become part of Merck KGaA’s Life Science business.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.